Xoma Corp. ( (XOMA) ) has released its Q2 earnings. Here is a breakdown of the information Xoma Corp. presented to its investors.
TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Xoma Corp., a biotech royalty aggregator, specializes in acquiring economic rights to future potential milestone and royalty payments associated with partnered commercial and pre-commercial therapeutic candidates. In its latest earnings report, Xoma Corp. highlighted a significant improvement in its financial performance, reporting a net income of $11.6 million for the first half of 2025, compared to $7.4 million in the same period in 2024. This increase was driven by higher income from purchased receivables and a reduction in operating expenses. The company’s total income and revenues for the first half of 2025 reached $29 million, more than doubling from $12.6 million in the previous year. Xoma Corp. also reported a strong cash position with $78.5 million in cash, cash equivalents, and restricted cash as of June 30, 2025. Looking ahead, Xoma Corp. remains optimistic about its financial outlook, supported by its robust portfolio of royalty rights and strategic acquisitions, which are expected to continue driving revenue growth and profitability.